TY - JOUR
T1 - Celiac disease and transglutaminase 2
T2 - A model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders
AU - Sollid, Ludvig M.
AU - Jabri, Bana
N1 - Funding Information:
Funding by the Research Council of Norway , the European Research Council , the South-Eastern Norway Regional Health Authority (to L.M.S.) and National Institutes of Health (grant R01 DK-67180 to B.J.) is acknowledged. We thank V. Abadie for discussion and preparation of the figures, and B. Sally and H. Fehlner-Peach for critical reading of the manuscript.
PY - 2011/12
Y1 - 2011/12
N2 - Posttranslational modification (PTM) of antigen is a way to break T-cell tolerance to self-antigens and promote autoimmunity. However, the precise mechanisms by which modifications would facilitate autoimmune T-cell responses and how they relate to particular autoimmune-associated MHC molecules remain elusive. Celiac disease is a T-cell mediated enteropathy with a strong HLA association where the immune response is directed mainly against deamidated cereal gluten peptides that have been modified by the enzyme transglutaminase 2. The disease is further characterized by autoantibodies to transglutaminase 2 that have extraordinary high disease specificity and sensitivity. There have been important advances in the knowledge of celiac disease pathogenesis, and these insights may be applicable to other autoimmune disorders where PTM plays a role. This insight gives clues for understanding the involvement of PTMs in other autoimmune diseases.
AB - Posttranslational modification (PTM) of antigen is a way to break T-cell tolerance to self-antigens and promote autoimmunity. However, the precise mechanisms by which modifications would facilitate autoimmune T-cell responses and how they relate to particular autoimmune-associated MHC molecules remain elusive. Celiac disease is a T-cell mediated enteropathy with a strong HLA association where the immune response is directed mainly against deamidated cereal gluten peptides that have been modified by the enzyme transglutaminase 2. The disease is further characterized by autoantibodies to transglutaminase 2 that have extraordinary high disease specificity and sensitivity. There have been important advances in the knowledge of celiac disease pathogenesis, and these insights may be applicable to other autoimmune disorders where PTM plays a role. This insight gives clues for understanding the involvement of PTMs in other autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=82955250010&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2011.08.006
DO - 10.1016/j.coi.2011.08.006
M3 - Review article
C2 - 21917438
AN - SCOPUS:82955250010
SN - 0952-7915
VL - 23
SP - 732
EP - 738
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 6
ER -